News

Categories
Sign up
Featured Posts
Archive
Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon

Israeli Company Set To Begin Testing New Radiation Cancer Therapy

An Israeli medical technology company is set to begin testing its new radiation cancer therapy in leading medical centers in Italy. The Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy) device delivers high-precision alpha radiation that is released when radioactive substances decay inside the tumor and kills cancer cells while sparing the surrounding healthy tissue, the company says. 3d illustration Cancer CellGETTY The company hopes to get approval from the European Commission by next year for the therapy. Early results from an ongoing clinical trial on 27 patients with squamous cell carcinoma (SCC) tumors at the Rabin Medical Center in Israel and the IRST (Istituto Scientifico Romag

Alpha Tau Medical Launches New Clinical Trials in Italy with Leading Cancer Centers, La Sapienza and

Trials will investigate the efficacy of its breakthrough cancer treatment, Alpha DaRT, in Squamous Cell Carcinoma (SCC) of the Skin, and Cutaneous and Mucosal malignant Neoplasia (CMN) TEL AVIV, Israel--(BUSINESS WIRE)--Alpha Tau Medical, developer of a breakthrough alpha-radiation cancer therapy, has announced the initiation of two new clinical trials evaluating the efficacy of the Alpha DaRT (Dіffusіng Alpha-emitters Radіatіon Therapy) with two leading medical centers in Rome, Italy. Following the approval from the Institutional Review Board (IRB), La Sapienza is initiating Alpha Tau’s clinical trial protocol for SCC of the Skin, and IFO is conducting their first study of Alpha DaRT for th

Newsletter - Issue no. 1

The Jewish New Year has now begun, providing us with a great opportunity to kick-off our quarterly Alpha Tau newsletter. This last year has seen fantastic progress. The significant operational, regulatory and clinical advancement was summarised by additional funding of $29 million that was recently raised from private and VC investors. Thank you to all our investors and partners – we cannot do this without you. We look forward to working together to realize the therapeutic potential of Alpha DaRT and develop a cancer treatment that can help save the lives of millions of patients around the world. I am delighted to share with you our latest news, developments and recent activities. E

Alpha Tau

Looking for clinical trials?

  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon